Cellular immunotherapy for refractory hematological malignancies

BACKGROUND: Acute myeloid leukemia (AML) and other aggressive refractory hematological malignancies unresponsive to upfront therapy remain difficult conditions to treat. Often, the focus of therapy is centered on achieving complete remission of disease in order to proceed with a consolidative stem c...

Descripción completa

Detalles Bibliográficos
Autores principales: Reagan, John L, Fast, Loren D, Safran, Howard, Nevola, Martha, Winer, Eric S, Castillo, Jorge J, Butera, James N, Quesenberry, Matthew I, Young, Carolyn T, Quesenberry, Peter J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689050/
https://www.ncbi.nlm.nih.gov/pubmed/23782682
http://dx.doi.org/10.1186/1479-5876-11-150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689050/
https://www.ncbi.nlm.nih.gov/pubmed/23782682
http://dx.doi.org/10.1186/1479-5876-11-150

Ejemplares similares